公开(公告)号：US20190382441A1

公开(公告)日：2019-12-19

申请号：US16439204

申请日：2019-06-12

Applicant: NOVARTIS AG

Inventor： Bernhard Hubert GEIERSTANGER ,  Jan GRUNEWALD ,  Yunho JIN ,  Weijia OU ,  Tetsuo UNO ,  Yongqin WAN ,  Xing WANG

IPC: C07K5/02 ,  A61K47/68 ,  C07K7/02 ,  C07K16/32

Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.

公开(公告)号：US20210228731A1

公开(公告)日：2021-07-29

申请号：US17253584

申请日：2019-06-19

Applicant: NOVARTIS AG

Inventor： Anthony Edward BOITANO ,  Matthew T. BURGER ,  Susan E. CELLITTI ,  Michael Paul COOKE ,  Catrin FINNER ,  Bernhard Hubert GEIERSTANGER ,  Si-Tuen LEE-HOEFLICH ,  HongNgoc Thi PHAM ,  Siew Ho SCHLEYER ,  Kathrin TISSOT ,  Tetsuo UNO ,  Yongqin WAN ,  Ben WEN ,  Qiang ZHANG

IPC: A61K47/68 ,  C07K16/28 ,  A61K38/07

Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.

公开(公告)号：US20210170043A1

公开(公告)日：2021-06-10

申请号：US16669291

申请日：2019-10-30

Applicant: NOVARTIS AG ,  ADURO BIOTECH, INC.

Inventor： Lisa BARNETT ,  Steven BENDER ,  Charles Y. CHO ,  Sarah COX ,  Jonathan Deane ,  Scott Martin GLASER ,  Xueshi Hao ,  Shailaja KASIBHATLA ,  Weijia OU ,  Tetsuo UNO ,  Yongqin WAN ,  Ben WEN ,  Tom Yao-Hsiang WU

IPC: A61K47/68 ,  C07K16/28 ,  A61K31/688 ,  A61P35/00

Abstract: Provided herein are immunoconjugates comprising an anti-DC-SIGN antibody conjugated to a STING agonist. Also disclosed are methods of making the immunoconjugates and methods of treating cancer using the immunoconjugates.

公开(公告)号：US20180244717A1

公开(公告)日：2018-08-30

申请号：US15961531

申请日：2018-04-24

Applicant: NOVARTIS AG

Inventor： Bernhard Hubert GEIERSTANGER ,  Jan GRUNEWALD ,  Yunho JIN ,  Weijia OU ,  Tetsuo UNO ,  Yongqin WAN ,  Xing WANG

IPC: C07K5/02 ,  C07K7/02 ,  A61K47/68 ,  C07K16/32

CPC classification number: C07K5/0205 ,  A61K47/6817 ,  A61K47/6851 ,  C07K7/02 ,  C07K16/32

Abstract: Disclosed herein are novel cytotoxic peptides of formula (I) as described herein: and the use of such peptides in making immunoconjugates (i.e Antibody Drug Conjugates) Also described herein are immunoconjugates (i.e Antibody Drug Conjugates) comprising such novel cytotoxic peptide linked to an antigen binding moiety, such as an antibody; where such immunoconjugates are useful for treating cell proliferative disorders. The invention further provides pharmaceutical compositions comprising these immunoconjugates, compositions comprising the immunoconjugates with a therapeutic co-agent, and methods to use these immunoconjugates and compositions for treating cell proliferation disorders.